Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.54 |
| ▸ | MTTP | P55157 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | APOB | P04114 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7607886 | 0.94 | EPHX2 (0.58) | NAMPTMTTPKMT2AMEN1APOB | |
| SCHEMBL6788420 | 0.91 | MTTP (0.57) | NAMPTMTTPKDRAPOBKDM1A | |
| SCHEMBL7605521 | 0.86 | RXFP1 (0.55) | NAMPTMTTPKDRAPOBRXFP1 | |
| SCHEMBL7608638 | 0.86 | KMT2A (0.58) | NAMPTMTTPKMT2AHTTMEN1 | |
| SCHEMBL7608096 | 0.85 | ROCK2 (0.50) | NAMPTMTTPKDRAPOBKDM1A | |
| SCHEMBL7041940 | 0.84 | KDM1A (0.56) | NAMPTMTTPAPOBKDM1AHDAC1 | |
| SCHEMBL7613634 | 0.84 | ROCK2 (0.56) | MTTPKDRAPOBRXFP1KDM1A | |
| SCHEMBL7613600 | 0.84 | MTTP (0.58) | NAMPTMTTPAPOBRXFP1EPHX2 | |
| SCHEMBL7607440 | 0.83 | MTTP (0.57) | MTTPHTTAPOBKDM1AHDAC1 | |
| SCHEMBL6798640 | 0.83 | HIF1A (0.53) | NAMPTMTTPKMT2AHTTKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | NAMPT 1407/4885MTTP 363/4885KMT2A 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.